Randomized Trialhigh evidence

Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.

Lancet (London, England)·April 11, 2026·PMID 41921523

Why it matters

This trial provides randomized evidence that a conservative approach to coronary artery disease before TAVI is safe in selected patients, potentially avoiding unnecessary procedures and their associated risks.

Infographic summary of Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled